Espansione meibomask® – The advanced LM® LLLT technology of the eye-light® system as a standalone solution

meibomask® is the answer to professionals that want to focus on the unique benefits of the Espansione LM® LLLT technology for the treatment of most ocular surface diseases.
 

What are the benefits?

Built with the same industrial design of our other solutions, meibomask® packs a punch when it comes to photobiomodulation technology—enabling patients and operators to benefit from everything Light Modulation® Low Level Light Therapy (LM® LLLT) has to offer:
 

Complete + direct treatment

meibomask® enables a full therapy, covering both lower and upper eyelids, to grant maximum efficacy in treating Dry Eye Disease (DED) induced by Meibomian Glands Dysfunction (MGD), Chalazion, Blepharitis, Sjögren’s Syndrome, Post-blepharoplasty.
 

Totaly painless

meibomask® and LM® LLLT provide patients with an entirely painless therapy. Near-infrared light is emitted on the skin at a medically-certified wavelength, generating endogenous heating by stimulating cells’ ATP production.
 

Quick

For patients, this means immediate relief, just 15’ after the therapy—for operators, it means delivering greater value to patients, with much less effort.
 

Easy

No training needed, no set-up time. It just works.
 

About LM® LLLT

The patented photobiomodulation technology from Espansione solicits cells’ mitochondria, triggering biochemical and biophysical reactions that stimulate them to a better protein synthesis. Thanks to the near-infrared emission of light, the tear lipid layer is increased and stabilized.
 
meibomask® provides patients with custom treatments based on the MGD severity level detected with me-check® screening. According to the severity of meibomian glands loss, meibomask® releases the correct amount of energy and treatment duration for every specific patient.